Trial reportClinical neuropharmacology
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
Trial report in Clinical neuropharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- The effectiveness of creatine treatment for Parkinson's disease: an updated meta-analysis of randomized controlled trials.BMC neurology · 2017Pooled it
- New Insights into Drug Development via the Nose-to-Brain Pathway: Exemplification Through Dodecyl Creatine Ester for Neuronal Disorders.Pharmaceutics · 2026Review
- Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson's Disease Patients.CNS & neurological disorders drug targets · 2024Review
- Review
- What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs.Neurology · 2022Review
- The Use of Medications and Dietary Supplements by Masters Athletes - a Review.Current nutrition reports · 2022Review
- The Proper Diet and Regular Physical Activity Slow Down the Development of Parkinson Disease.Aging and disease · 2021Review
- Review
- Do caffeine and more selective adenosine AParkinsonism & related disorders · 2020Review
- Caffeine in Kidney Stone Disease: Risk or Benefit?Advances in nutrition (Bethesda, Md.) · 2018Review
- Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease.Movement disorders : official journal of the Movement Disorder Society · 2018Article
- Chronic Caffeine Treatment Protects Against α-Synucleinopathy by Reestablishing Autophagy Activity in the Mouse Striatum.Frontiers in neuroscience · 2018Article
- The emerging science of precision medicine and pharmacogenomics for Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2017Review
- Caffeine, creatine, GRIN2A and Parkinson's disease progression.Journal of the neurological sciences · 2017Article
- Beyond muscles: The untapped potential of creatine.International immunopharmacology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
Abstract
objectiveIncreased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. However, in a previous study, an exploratory analysis suggested that, in patients taking creatine, caffeine intake was associated with a faster rate of progression. In the current study, we investigated the association of caffeine with the rate of progression of PD and the interaction of this association with creatine intake.
methodsData were analyzed from a large phase 3 placebo-controlled clinical study of creatine as a potentially disease-modifying agent in PD. Subjects were recruited for this study from 45 movement disorders centers across the United States and Canada. A total of 1741 subjects with PD participated in the primary clinical study, and caffeine intake data were available for 1549 of these subjects. The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified Parkinson Disease Rating Scale score and the interaction of this association with creatine intake were assessed.
resultsCaffeine intake was not associated with the rate of progression of PD in the main analysis, but higher caffeine intake was associated with significantly faster progression among subjects taking creatine.
conclusionsThis is the largest and longest study conducted to date that addresses the association of caffeine with the rate of progression of PD. These data indicate a potentially deleterious interaction between caffeine and creatine with respect to the rate of progression of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.